

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))

Docket No. 5711-D1-01-MG

74.		=
	4	=
•	-	
• • •	Н.	_
w.	т.	
VI.		=
• •	11	==
_	7	=
~,	1.0	
	~	=

	- (0	3 CFR 1.57(b) 01 1.57	(C))	5/11-D1-01-MG	⊃2							
In Re Application	n Of:	DANETTE ANDREA DUDLEY, E	ET AL.		10828							
Serial N	Serial No. Filling Date Examiner Group Art Uni											
Title: QUINO	XALINO	NES AS SERINE PROTEASE INI	HIBITORS SUCH AS FACTO	R XA AND THROMBIN								
		Assistant Com	ddress to: nmissioner for Patents pton, D.C. 20231									
of a na three n applica	ational ap nonths of ation; befo	Disclosure Statement submitted plication other than a continued the date of entry of the national are the mailing of a first Office Acfiling of a request for continued expressions.	prosecution application unde stage as set forth in 37 CFR tion on the merits, or before the	r 37 CFR 1.53(d); within 1.491 in an international ne mailing of a first Office	Commence of the commence of th							
		37 C	FR 1.97(c)									
CFR 1. Final A	.97(b), pr Action und	Disclosure Statement submitted ovided that the Information Disc der 37 CFR 1.113, a Notice of sprosecution in the application, a	closure Statement is filed before filed before allowance under 37 CFR	ore the mailing date of a								
□ t	the staten	nent specified in 37 CFR 1.97(e);										
•		OR			<u></u>							
□ t	the fee se	t forth in 37 CFR 1.17(p).										

TRANSMITTAL OI	Docket No.		
In Re Application: I	DANETTE ANDREA DUDLEY, I	ET AL.	Je828 U
Serial No.	Filing Date	Examiner	Group Art Unit
QUINOXALINON	NES AS SERINE PROTEASE IN	HIBITORS SUCH AS FACTOR	R XA AND
	Рауг	ment of Fee	
as described belo Charge th Credit any Charge at Certificate of T	mount of is attainmissioner is hereby authorized w. A duplicate copy of this sheen amount of yoverpayment. Transmission by Facsimile* ent and authorization to charge deposite the united States with the United States	Certificate of Mailing I certify that this document as first class mail under addressed to the Assistant Washington, D.C. 20231.	g by First Class Mail and fee is being deposited with the U.S. Poetal Service r 37 C.F.R. 1.8 and is
L'	y only be used if paying by	Typed or Printed Name of I	Person Mailing Certificate
Heidi M. Berven Registration No. 48,951 Warner-Lambert Company 2800 Plymouth Road Ann Arbor, MI 48105 Tel. (734) 622-5218 Fax (734) 622-1553	gnature	Dated: January 4, 2002	
cc:			

x

X

x

X

X

														#4	
												S	Sheet _1	_ of _2	
FORM PTO (Rev. 2-32)	Ċ	J.S. OM RAI	ME	RC	E P	ΑT	EN	ΓΑΝ		TTY. DOCKET NO. 5711-D1-01-MG	SERLA	SERIAL NO.			
	NFORMAT FATEMEN						_			PPLICANT DANETTE A. DUDLEY, ET A	AL.			-	
	(Use severa	al she	ets i	fnec	essa	ry)			F	LING DATE	GROU	P			
								U.S	S. PAT	ENT DOCUMENTS	' S				
EXAMINER INITIAL		DO			DATE	TE NAME				FILING DATE APPROPRIATE					
		4	0	8	2	7	3	5	4/4/78	Jones et al.	260	112.5 R			
		4	0	8	2	7	3	6	4/4/78	Jones et al.	260	112.5 R			
		4	8	7	0	1	7	5	9/26/89	Suzuki et al.	544	354			
	-	\vdash	_			-		-							
					'	ŀ	·-	RE	IGN P	ATENT DOCUMEN	NTS				
		DC	OCU	JMI	ENT			BER		COUNTRY		S SUBCLAS	SS TRANS	LATION	
													YES	NO	
		1	2	5	4	3	4	8	11.10.89	Japan				х	
		9	7	0	7	1	1	6	27.02.97	WO				х	
		63	1	4	5	2	7	2	17.06.88	Japan				x	

4

1

1 3 3

0 1 4 2

2

0 6

6

8

8

15.01.98

24.12.97

02.04.98

wo

wo

wo

15.01.98 WO revised version

0

4 8 7

8

7

8

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

	PCT International Search Report, PCT/US98/26704						
	Lappato et al., "X-ray structure of anitstasin at 1.9 Å resolution and its modeled complex with blood coagulation factor Xa", The EMBO Journal, Vol. 16, No. 17, 5151-5161, 1987						
	Mellott et al., "Enhancement of Recombinant Tissue Plasminogen Activator-induced Reperfusion by Recombinant Tick Anticoagulant Peptide, A Selective Factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", Fibrinolysis, 7, 1993, 195-202						
	Lynch et al., "Primary Prevention of Coronary Arterial Thrombosis with the Factor Xa Inhibitor rTAP in a Canine Electrolytic Injury Model", Thrombosis and Haemostasis, 74 (2) 640-5, 1995 Schaffer et al., "Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide", Circulation, 1991, 84:1741-1748						
	Fioravanti, et al., "Antithrombotic Activity of Recombinant Tick Anticoagulant Peptide and Heparin in a Rabb Model of Venous Thrombosis", Thrombosis Research, 71, 317-324, 1993						
EXAMINER	DATE CONSIDERED						

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ΓAN	D		TTY. DOCKET NO. 7111-D1-01-MG	SERIA	SERIAL NO.				
			N DISC						PPLICANT DANETTE A. DUDLEY, ET AL.	-, L					
(Use several sheets if necessary)									LING DATE	GROU	JP				
	-					II.S	S P	<u> </u>	ENT DOCUMENTS	<u>. I</u>			-		
EXAMINER INITIAL	De	осим	ENT	NUM			-	NAME	CLASS	CLASS SUBCLASS		DATE PRIATE			
				Ш											
		L_									l				
					FO	RE	IGN	J P	ATENT DOCUMENT	rs					
	-	D	осим	ENT				_	COUNTRY	CLA	SS SUBCLA	SS TRANS	LATION		
		\bot				,						YES	NO		
				\sqcup	+	┞	<u> </u>								
			Щ										<u> </u>		
OT	HER	R DC	Wong	et al.	, "An	tithro	mboti	c Ac	ng Author, Title, Date tions of Selective Inhibitors of Blo	od Coagula			odels of		
								Research, Vol. 83, No. 2, 117-126, 1996							
								Annual Reports in Medicinal Chemistry, 31, 51-60, 1996 actor Xa Inhibitors", Current Pharmaceutical Design, 1996, 2, 531-542							
				zczak	and N	Merei	ter, "S	Syntheses in the series of pyrazolyl-substituted quinoxalines", Heterocycles, Vol.							
			Leardini et al., "Peroxydicarbonate-Mediated Oxidation of N-(ortho-Aryloxyphenyl) and N-Arylaminophenyl)aldimines", <u>Tetrahedron</u> , Vol. 51, No. 44, 12143-12158, 1995												
		Awad and Hassan, "Studies in Vilsmeier-Haack Reaction. Application to Quinoxalinones", Coll Chem. Commun., Vol. 55, 1990, 2715-2721										ech.			
			Otoma a]quin	isu et oxalii	al., " ne", <u>Y</u>	Quino akuga	oxaline aku Za	e 1,2 asshi	.2-Dihydroimidazo[1,2-a]-quinoxaline 1,2-Dihydro-3H-pyrimido[1,2- hi, 90 (11), 1391-1395, 1970						
			Azaqu	inoxa	lines"	, <u>Indi</u>	an Jou	amoebic Agents: Syntheses of Substituted Indophenazines, Azaindophenazines & urnal of Chemistry, Vol. 12, 1974, 124-128							
		L	1989						Perivatives as Potential Antitumora						
			Hahn et al., "Effect of Mepyramine and Spasmolytic Agents on Guinea-Pig Anaphylaxis with Special R to the Protracted Shock", Arch. Int. Pharmacodyn., 199, 108-121, 1972									leference			
		Chemical Abstracts, Vol. 111, No. 9, 1989, abstract 78027u Morrow and Regan, "Some Unusual Oxidation Reactions of 1,3-Diaryl-3,4-dihydro-7-methoxy-2 quinoxalineones", J. Org. Chem., Vol. 36, No. 1, 1971, 27-31								2/475					
										oxy-2(1H)-					
									of N-(-phenylalkyl)substituted qu 97, 357-366	inoxaline-2	2(1H)-ones an	d -thiones",			
			Kurasa oxo-1,	wa e 2,3,4	t al., ' -tetral	'Revi	sed St quinox	ructi (alin	are for the Production from the Re with Nitrous Acid", Chem. Phar	e Production from the Reaction of 3-Hydrazinocarbonylmethylene-2-trous Acid", Chem. Pharm. Bull., 32 (10), 4140-4143, 1984					
EXAMINER			L						DATE CONSIDERED						

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.